Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

@article{Tawbi2022RelatlimabAN,
  title={Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.},
  author={Hussein A. Tawbi and Dirk Schadendorf and Evan J. Lipson and Paolo Antonio Ascierto and Luis Matamala and Erika Castillo Guti{\'e}rrez and Piotr R Rutkowski and Helen J Gogas and Christopher D. Lao and J.J. De Menezes and Stéphane Dalle and Ana Arance and Jean Jacques Grob and Shivani Srivastava and Mena Abaskharoun and Melissa Hamilton and Sarah Keidel and Katy L. Simonsen and A.M. Sobiesk and Bin Li and Frank Stephen Hodi and Georgina V. Long},
  journal={The New England journal of medicine},
  year={2022},
  volume={386 1},
  pages={
          24-34
        }
}
BACKGROUND Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking antibody, has been shown to be safe and to have antitumor activity in patients with previously treated melanoma, but the safety and activity in patients with previously untreated melanoma need investigation. METHODS In this phase 2-3, global, double… 

Figures and Tables from this paper

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination With Nivolumab
TLDR
Preclinical studies demonstrate that relatlimab specifically blocks the interaction between LAG-3 and its ligands, and provide a biological rationale for combining relat Limab with the anti−PD-1 antibody nivolumab as an effective cancer immunotherapeutic strategy.
Nivolumab Plus Relatlimab: First Approval
TLDR
This article summarizes the milestones in the development of this combination therapy leading to this first approval for unresectable or metastatic melanoma in adult patients and paediatric patients aged ≥’12 years who weigh ≥ 40 kg.
Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
TLDR
The combination therapy was safe and tolerable with an absence of immune-related adverse events (irAE) of special interest, but with four of nine patients experiencing a CTCAE grade 3 AE, did not improve the clinical outcome beyond the expected limited efficacy of approved immunotherapy alone.
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma
TLDR
The safety and efficacy data of all the agents currently approved for the first-line treatment of advanced melanoma are discussed, identifying factors that influence the choice of a single agent rather than combination therapy and the potential biomarkers of response, effects of long-term toxicity, and options after progression.
Clinical landscape of LAG-3-targeted therapy
Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
TLDR
Improved efficacy of PD-1 blockade with concurrent cisplatin-based chemoradiotherapy is demonstrated using an immune-competent murine model of HNSCC and the peripheral blood immune response to therapy is characterized, highlighting potential competing mechanisms of immune evasion.
Systemic immune dysfunction in cancer patients driven by IL6 induction of LAG3 in peripheral CD8+ T cells.
TLDR
The data suggest that additional studies are warrented to determine if the combination of increased LAG3IC in peripheral CD8+ T cells and elevated systemic IL6 can serve as predictive biomarkers and identify which cancer patients may benefit from LAG 3 blockade.
Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
TLDR
Accumulating follow-up data and ongoing phase III studies must prove if neoadjuvant systemic therapy is superior to surgery followed by standard-of-care adjuvant therapy to improve recurrence-free survival.
Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
TLDR
An overview of the latest developments in immunotherapeutic registrations for cancer patients worldwide is provided, including new drugs targeting already known molecules are being tested, and new potential targets are being explored.
Combination Approaches to Target PD-1 Signaling in Cancer
TLDR
Together, it is found that all of these proteins are logical and promising targets for combination therapy, and that with a deeper mechanistic understanding they have potential to improve the response rate and decrease adverse events when thoughtfully used in combination with checkpoint inhibitors.
...
...

References

SHOWING 1-10 OF 26 REFERENCES
Nivolumab in previously untreated melanoma without BRAF mutation.
TLDR
Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
TLDR
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
TLDR
Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with n ivolumAB alone than with ipil optimumab alone.
Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.
TLDR
Preliminary efficacy of BMS-986016 + nivo in pts with MEL whose disease progressed on/after prior anti–PD-1/PD-L1 therapy, along with updated safety from all dose expansion pts are described.
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
TLDR
A strong synergy between the PD-1 and LAG-3 inhibitory pathways in tolerance to both self and tumor antigens is defined and it is argued strongly that dual blockade of these molecules represents a promising combinatorial strategy for cancer.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
TLDR
Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivoliumab alone than in those who received ipil optimumab alone, with no apparent loss of quality of life in the patients whoreceived regimens containing nivolinumab.
Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma
TLDR
This is the first PD-L1 IHC test to receive FDA approval as a complementary diagnostic in melanoma patients whereby positive PD- L1 expression is correlated with the magnitude of nivolumab treatment effect.
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
TLDR
This 6.5-y analysis represents the longest follow-up from a phase 3 melanoma trial in the modern checkpoint inhibitor combination therapy and targeted therapy era and shows durable improved outcomes with NIVO + IPI and NivO vs IPI in pts with advanced melanoma.
...
...